Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease. Our aim was to estimate the total economic burden of NASH and advanced NASH in the United States. We constructed lifetime Markov models for all stages of NASH and a separate model to specifically identify the increased burden of advanced NASH (fibrosis stage >3). The models comprised patients aged 18+, who moved through seven different health states. We used a lifetime horizon with 1-year cycles for each transition. Cohort size was estimated using US population data, and prevalence and incidence rates were obtained from the literature. Transition probabilities between states were derived from meta-analyses. Costs included inpatient, outpatient, professional services, emergency department, and drug costs, which were obtained from the Center for Medicare and Medicaid Services Fee Schedule 2017 and published data. All future costs were discounted at an annual rate of 3%. Our models estimated that there are 6.65 million adults (18+ years old) with NASH in the United States and that there were 232,000 incident cases in 2017. Lifetime costs of all NASH patients in the United States in 2017 will be $222.6 billion, and the cost of the advanced NASH population will be $95.4 billion. Conclusion: NASH, especially advanced NASH, is associated with high lifetime economic burden; in the absence of treatment, the total direct costs of illness for these patients will continue to grow, and these costs would be even greater if the societal costs are included. (Hepatology 2019;69:564-572). N onalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide.
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
N onalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide.
(1- 3) Although NAFLD has been associated with increased mortality, predominantly from cardiovascular causes, nonalcoholic steatohepatitis (NASH) can lead to cirrhosis and its associated mortality. (4) (5) (6) (7) (8) (9) (10) (11) In this context, NASH is rapidly becoming one of the most common indications for liver transplantation (LT) and one of the most common causes of hepatocellular carcinoma (HCC) in the United States. (12) (13) (14) (15) In addition to its clinical impact, NAFLD and NASH can impair patients' health-related quality of life. (16, 17) Finally, NAFLD and NASH can be associated with significant health care use. (18, 19) Despite mounting evidence about the clinical and economic implications of NAFLD and NASH, very little data have been published to estimate the economic burden of NAFLD. In our previous model, we developed a Markov model to estimate the economic burden of NAFLD in the United States and four European countries. (20) Using a prevalence model, we estimated that in 2017 there were 64 million cases in the United States and 52 million cases in the four European countries, with an estimated annual burden of $103 billion and €35 billion, respectively. (20) Although this study showed the tremendous economic impact of NAFLD, it may be more urgent to focus on those NAFLD subjects who are at the highest risk for adverse outcomes. In this context, there are a number of studies that have suggested that subjects with histologic NASH are at risk for progressive liver disease and that those with significant fibrosis are at the greatest risk.
(1, [6] [7] [8] [9] [10] 21) In fact, the stage of fibrosis has been shown to be the only and most reliable predictor of liver-related mortality. (6) (7) (8) (9) (10) (11) (12) Therefore, one can argue that these are the patients with the most urgent need for treatment. In this context, it will be important to determine the economic burden of NASH, especially NASH with advanced fibrosis, for the United States. Therefore, our aim was to use a Markov decision analytic model to estimate the burden of illness for patients with NASH and those with advanced fibrosis NASH in the United States.
Patients and Methods

MoDel aND patieNt populatioN
We performed an economic analysis including NASH patients with all stages of fibrosis along with advanced stages of NASH. Because there is some interest only in NASH patients with advanced fibrosis, we also developed a submodel based on the first model to focus on the higher costs and outcomes associated with advanced fibrosis (stage 3 and higher). The data for NASH with advanced fibrosis are provided in the Supporting Information. We developed both prevalence and incidence modules for the model, which was built exclusively in Microsoft Excel using the disease-specific Markov structure presented in Fig. S1 .
Model Design
We created a Markov model which comprised all stages of NASH. The Markov health states were NASH with no fibrosis (F0), fibrosis stage 1 (F1), fibrosis stage 2 (F2), fibrosis stage 3 (F3), compensated cirrhosis (CC), decompensated cirrhosis (DCC), HCC, LT, 1-year post-LT (1yPLT), post-LT (PLT), and death (Fig. 1) . Our model used a lifetime horizon, with each member of the cohort passing through the stages until all cohort members had reached one of the absorbing death states. The model cycle length was 1 year. In the all NASH model, patients entered the model at NASH F0 and remained in or transitioned to another NASH health state at the end of each cycle. Fibrosis regression was permitted from F1 to F0, F2 to F1 and F0, F3 to F2 and F1, and CC to F3. LT was considered for DCC and HCC patients. All patients who underwent LT transitioned to a tunnel state for their first-year PLT state. Death was included as three absorbing states in the model-liver-related mortality, cardiovascular mortality, and other mortality. The advanced-stage NASH model was the same as the all NASH model, except that patients enter the model at stage F3.
incidence Calculations
Lifetime Markov cohort models were constructed to estimate the economic burden of incident NASH (all NASH and advanced) in the United States. The incidence-based modules were comprised of four age cohorts: 18-39, 40-59, 60-89, and 90+. The incidence rate of NAFLD was taken from published literature (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 20) and based on the estimate that NASH comprises 7%-30% of NAFLD prevalence,
(1) we assumed that the annual incidence rate for NASH would be 20% of the reported rate of NAFLD. (22) In our model, the incidence rate of NASH per 100,000 person-years was 28 for age group 18-39, 81.4 for age group 40-59, 103 for age group 60-89, and 30 for the 90+ age group aRtiCle iNFoRMatioN: (Supporting Table S1 ). (23) The number of patients entering each annual cohort model was estimated using the US population projection data and previously stated annual incidence rate of NASH for each age cohort. (23, 24) The estimated number of patients in each age cohort began their model simulation at F0 in the all NASH model and F3 in the advanced NASH model annually. We estimated that the number of patients entering the advanced NASH model would be 10% of the patients in the all NASH model (Supporting Table  S2 ), based on results from the all NASH model.
prevalence Calculations
The prevalence modules for the all NASH and advanced NASH models were comprised of seven age cohorts: 18-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+. For the prevalence-based modules, population size at the start of each model was based on estimated NASH prevalence in each age cohort in 2017. (20) For the advanced NASH model, we assumed that the cohort size starting in states F3 and above was 10% of the size of the all NASH model, based on results from the all NASH model (Supporting Table S2 ).
transition probabilities
The annual transition probabilities for the all NASH model are shown in Table 1 . Transition probabilities were derived for each health state from clinical trials, systematic literature reviews, meta-analyses, and our previously published model.
(1, 2, [6] [7] [8] [9] [10] [11] 20, 25) The transition probabilities for F1, F2, F3, and CC to later stages of liver disease were obtained from a recent meta-analysis. (26) Transition probabilities from fibrosis states to HCC and CC to DCC were obtained from our previously published study.
(1, 20) The annual incidence rate of HCC in CC patients was estimated to be 2.6%, (27) and the probability of LT in HCC-NASH patients was 41%. (12) Cardiovascular mortality and liver-related mortality for health states were derived from several published sources.
(1,9,28-30) Other mortality was applied in 5-year intervals to include death from other causes in the general population. (31) Transition probabilities from DCC and HCC to LT, from LT to 1yPLT, and from 1yPLT to PLT, were age-dependent and based on consultation with hepatology experts (Supporting Table S3 ). All other transition probabilities were assumed to be the same for all health states and age groups and between the all NASH and advanced NASH models. This assumption was made as progression in later stages of NASH seems to be independent of age. (32) 
Cost inputs
A combination of microcosting and gross costing methods was used to estimate the costs associated with each health state in our model. As this study was conducted from a US payer perspective, we estimated only the direct medical costs associated with NASH health states. We included costs for inpatient hospitalization, outpatient visits, emergency room, drugs, laboratory, imaging, and screening tests ( Table 2 ). All costs were inflated using the Consumer Price Index and reported in 2017 US dollars. Resource use in the first year and subsequent years for F0, F1, F2, and F3 patients in the all NASH model was based on input from hepatology experts. Costs for outpatient visits, laboratory, imaging, and screening for hepatitis C and B tests were based on Current Procedural Terminology codes using the Center for Medicare and Medicaid Fee Schedule 2017. The costs for CC, DCC, and HCC were derived from a study on the costs of advanced nonalcoholic liver disease in the Veteran's Administration. (33) There are no NASHspecific costs available for patients with advanced liver disease. Nevertheless, we assumed that once patients reach advanced liver disease, the costs of monitoring and management are driven by disease severity rather than the etiology of liver disease. In this context, we assumed that the costs of HCC, LT, and PLT would be the same as observed in hepatitis C patients, except for the cost of antiviral drugs, which were excluded from the analysis. Therefore, the costs for LT, 1yPLT, and PLT stages were derived from a retrospective study which reported incremental all-cause costs for hepatitis C virus (HCV) patients relative to non-HCV patients. (34) We assumed that state costs would not vary among different age groups. An annual 3% discount rate was applied to all costs. (35) aNalysis Our outcome measures included 5-year costs, 10-year costs, and lifetime costs for every age cohort in all models. We also estimated number of person-years in the HCC state, number of LTs, total cardiovascular 
Results
Our model results estimate that 6.6 million prevalent adult cases of all NASH and 232,000 incident adult cases of all NASH are predicted in the United States in 2017 (Tables 3 and 4) . We found that 79% of the 2017 adult prevalent NASH population was comprised of patients aged 50+ and that 90% of the 2017 adult incident population was older than 40 years. Our model predicts that there are 665,000 cases of advanced NASH, with 23,000 incident cases in 2017, totaling 688,000 cases (Supporting Table  S2 ). Additionally, 51% of incident advanced NASH patients are aged 60-89.
Results FoR tHe all NasH MoDel
In the all NASH model, the lifetime cost per patient for the 232,000 incident cases predicted in 2017 is highest in the 18-39 age cohort and would amount to $72,800 per case. In the prevalence module, 134,000 prevalent patients aged 18-29 have a lifetime cost per patient of $77,100 per case. The total lifetime cost for all stages of NASH amounted to $214.1 billion in the prevalent population and $7.8 billion in the 2017 incident population. The pooled incident and prevalent lifetime cost for all NASH is estimated to be $222 billion (Table 4) .
We predict that there will be an average of 245,000 incident cases of NASH annually between 2017 and 2060, totaling 10.8 million new cases over that time frame. The total lifetime costs of these cases will amount to $359 billion (Supporting Table S4 ).
Cardiovascular mortality was estimated to be 296,700 deaths for the prevalent all NASH population and 10,400 deaths for the 2017 incident all NASH population. Liver-related mortality was estimated to be 1.01 million for the prevalent population and 36,400 for the 2017 incident all NASH population.
We estimated that over a lifetime horizon, 259,000 LTs would be performed in the prevalent population and 10,800 for the 2017 incident cohort. Person-years spent in the HCC state were 366,700 for the prevalent population and 13,000 for the 2017 incident cohort (Table 5) .
Results for the advanced NASH model are presented in the Supporting Information.
seNsitiVity aNalysis
One-way deterministic sensitivity analysis was performed to test model output sensitivity to changes in state costs and transition probability inputs. The models were most sensitive to F3 state costs (±6.23%) and HCC costs (±7.32%). Overall, no significant change in total cost was observed when different health state costs were varied by 20%. Base costs were assumed to be the same for all age groups; thus, tornado diagrams showed a similar pattern among all four models and all age groups. Sensitivity analysis on transition probabilities showed that transitions from any starting state to a mortality state (liver-related mortality, cardiovascular mortality, other mortality) had the most impact on costs in both models, particularly in older age groups. Changing the mortality rate in the population for each age by ±10% of the base case showed a change in average lifetime costs from 2% to 20% in the 40-59 age group. Lifetime average cost was most sensitive to changes in transition probabilities from DCC, HCC, and PLT to liver-related mortality. The second most significant impact on overall cost was change in transition probabilities to increase fibrosis regression (e.g., moving from F3 to F2, F2 to F1, etc.). Increasing fibrosis regression transition probabilities by ±10% base case showed a 3%-8% reduction in lifetime costs for the advanced NASH population. We have shown the most significant results from sensitivity analysis in Table 6 .
Discussion
This study provides estimates for the current and future clinical and economic burden of NASH and advanced NASH in the adult population of the United States. Our incidence-based model also provides an estimate for the number of adults who will develop NASH each year in the future.
This model indicates that there exists already an immense clinical burden of NASH in the United States. The increased clinical burden directly influences the economic burden of chronic diseases such as NASH on the society. We used a Markov model to estimate the lifetime economic burden of NASH with no fibrosis and advanced NASH. We created both incidence-based and prevalence-based modules to present a complete picture of the future economic burden of NASH and advanced NASH in the United States. Due to the lack of treatment and slow progression of the disease, the costliest per-patient lifetime economic burden is observed in the young population.
It is important to note that we did not include either costs of comorbidities, nonmedical costs, or the societal costs of NASH. The rapid rise in NAFLD prevalence parallels the rise in diabetes and obesity in the adult US population, which will increase the clinical burden and eventually the economic burden of NASH. (22, 36, 37) It is known that NASH negatively impacts patient-reported outcomes and potentially work productivity. (38) If we include these additional costs, the total costs to the society could be enormous.
Sensitivity analysis showed that the direct medical costs of advanced fibrosis and HCC care associated with NASH had the most significant impact on the total health care costs. It also showed that increases in fibrosis regression would be impactful in reducing lifetime costs as 1 year spent in a fibrosis state is significantly less expensive than a year spent with advanced NASH stage.
Our study did have certain limitations. First, we did not have exact data on the annual incidence rate of NASH and therefore assumed it to be 20% of the available published estimates of incidence for NAFLD, and we maintained a constant annual incidence rate for each age group throughout the model. Further prospective longitudinal research is required to estimate the current and predicted rise in incidence of NASH more accurately. Second, the inherent assumption of "lack of memory" within a Markov transition state implies that the probability of moving from one state to another is independent of the experiences of previous cycles. We minimized the effects of this assumption by changing the probability of death as the population aged in our model. We also adjusted the transition rates for DCC and HCC to LT as the probability of receiving LT decreases in older patients. Third, we could not get the exact proportion of the population suffering from diabetes and/or obesity. Based on a review of the published literature, around 30%-40% of the NAFLD population is estimated to have diabetes. If drug costs for diabetes or other comorbidities are added for patients with earlier liver disease, total costs will increase. Fourth, the costs for advanced stages of liver disease were obtained from a study on the published literature for patients with advanced nonalcoholic liver disease and non-NASH patients. However, we did account for the cost of HCV medications. In this context, we believe that once patients with any liver disease reach advanced stages, the costs of management of DCC, HCC, LT, 1yPLT, and PLT would remain the same irrespective of the disease etiology. Fourth, although we discounted future costs at a rate of 3% annually, we did not take into account the rising cost of health care and that future costs for each state of advanced NASH patients will be more expensive, even accounting for inflation.
It is important to note that we have only reported costs from the payer perspective and that our results did not include the costs borne by society. Analyzing the costs associated with lost work productivity, caregivers' costs, and the direct nonmedical costs such as travel, food, and lodging will provide a better picture of the cumulative economic burden of NASH. In summary, our study provides an overall estimate of the cost burden of NASH and advanced NASH in the United States in 2017. This study clearly indicates the enormous economic burden of NASH and advanced NASH and the urgency to develop effective treatment for patients with advanced NASH. Abbreviation: LRM, liver-related mortality.
